New Insulin From Novo Nordisk Reveals Long-Term Efficacy in Both Children and Adolescents
News, Type 1 Diabetes News
Novo Nordisk released new data from the clinical trial, BEGIN YOUNG 1, a study comparing a once-daily Tresiba (insulin degludec) regime, an ultralong-acting basal insulin analogue, with an insulin detemir regime, ... Read more